iSpecimen (ISPC) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue grew 76% year-over-year to $2.86 million, driven by higher specimen count, increased average selling price, and operational improvements such as the Next-Day Quote and Supplier Refresh programs.

• Net loss for Q2 2024 narrowed to $2.1 million ($0.19/share), down from $3.5 million ($0.39/share) in Q2 2023, reflecting improved operating leverage and cost reductions.

• Strategic reductions in capital, workforce, and operational expenditures, along with cost-cutting initiatives, have positioned the company for revenue growth and improved profitability.

• Leadership team strengthened with the appointment of a new SVP of Sales & Business Development to drive sales and business development.

• The company continues to face substantial doubt about its ability to continue as a going concern due to recurring losses and negative working capital.

Financial highlights

• Q2 2024 revenue was $2.86 million, up from $1.63 million in Q2 2023; six-month revenue reached $5.15 million, up from $4.58 million.

• Q2 2024 net loss: $2.1 million ($0.19/share), improved from $3.5 million ($0.39/share) in Q2 2023; six-month net loss: $5.0 million ($0.49/share), improved from $5.9 million ($0.66/share) in the prior year.

• Cost of revenue for Q2 2024 rose 67% to $1.42 million, reflecting higher specimen volume and cost per specimen.

• General and administrative expenses for Q2 2024 decreased 40% year-over-year to $1.05 million.

• Cash and available-for-sale securities totaled $2.15 million as of June 30, 2024, down from $5.01 million at year-end 2023.

Outlook and guidance

• Management remains focused on operational efficiency, cost management, and driving toward profitability, with ongoing initiatives to secure additional working capital.

• If revenue growth or cost containment is insufficient, further scaling down of operations may occur.